Rising statin use and effect on ischemic stroke outcome

BMC Medicine

Volumn 2, Issue , 2004, Pages

  Yoon, Sung Sug ^a   Dambrosia, James ^a   Chalela, Julio ^a   Ezzeddine, Mustapha ^b   Warach, Steven ^a   Haymore, Joseph ^c   Davis, Lisa ^a   Baird, Alison E ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b EMORY UNIVERSITY   (United States)

^c WASHINGTON ADVENTIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TICLOPIDINE; TRIACYLGLYCEROL; WARFARIN;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL OBSERVATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG USE; FEMALE; HEALTH PROGRAM; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; RATING SCALE; RISK FACTOR; SCORING SYSTEM; SELF REPORT; STATISTICAL ANALYSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; BRAIN ISCHEMIA; LENGTH OF STAY; MORTALITY; RISK; STATISTICAL MODEL; SURVIVAL RATE;

AGED; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; LENGTH OF STAY; LOGISTIC MODELS; MALE; ODDS RATIO; STROKE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3242713612     PISSN: 17417015     EISSN: None     Source Type: Journal    
DOI: 10.1186/1741-7015-2-4     Document Type: Article

References (33)

1. Bucher HC, Griffith LE, Guyatt GH: Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 1998, 128:89-95.
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto A. M., Jr.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
3. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995, 346:1647-1653.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
6. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998, 97:1440-1445.
7. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
8. Jialal I, Devaraj S: Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 2001, 116 Suppl:S108-15.
9. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. Jama 1998, 279:1643-1650.
10. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
11. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA: Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001, 32:980-986.
12. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998, 95:8880-8885.
13. Kawashima S, Yamashita T, Miwa Y, Ozaki M, Namiki M, Hirase T, Inoue N, Hirata K, Yokoyama M: HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003, 34:157-163.
14. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, Chopp M: Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003, 53:743-751.
15. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
16. Laufs U, Liao JK: Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000, 10:143-148.
17. Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, Endres M: Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003, 34:551-557.
18. Lattimore SU, Chalela J, Davis L, DeGraba T, Ezzeddine M, Haymore J, Nyquist P, Baird AE, Hallenbeck J, Warach S: Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience. Stroke 2003, 34:e55-7.
19. Brott T, Adams H. P., Jr., Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al.: Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989, 20:864-870.
20. Goldstein LB, Samsa GP: Reliability of the National Institutes of Health Stroke Scale. Extension to non-neurologists in the context of a clinical trial. Stroke 1997, 28:307-310.
21. Adams H. P., Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh E. E., 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41.
22. Rankin J.: Cerebral vascular accidents in patients over the age of 60, II:Prognosis. Scott Med J. 1957, 2:200-215.
23. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988, 19:604-607.
24. Jonsson N, Asplund K: Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke 2001, 32:1112-1115.
25. Bushnell CD, Goldstein JL, Newby LK, Lin F, Simon JA: Reduced mortality with statin use in the Heart and Estrogen/Progestin Replacement Study (HERS). Stroke 2003, 34:320 (Abstract).
26. Moonis M, Goldstein LB, Sandage BW, Schwiderski U, Fisher M: Post-stroke statins improve outcome after acute ischemic stroke. Neurology 2003, 60 (suppl 1):A327 (abstract).
27. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS: Effect of lipidlowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001, 357:1063-1068.
28. Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E: Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002, 89:860-861.
29. Stenestrand U, Wallentin L: Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001, 285:430-436.
30. Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, McGuire DK, Moliterno DJ, Verheugt FW, Weaver WD, Califf RM: Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002, 287:3087-3095.
31. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
32. Lalouschek W, Lang W, Greisenegger S, Mullner M: Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stroke 2003, 34:105-110.
33. Ichihara K, Satoh K: Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 2002, 359:2195-2198.